Race has been shown to impact receipt of and outcomes following hepatobiliary surgery. We sought to determine if racial disparities in the management of hepatocellular carcinoma persist.
Information on patients with hepatocellular carcinoma diagnosed between 2012 and 2016 was obtained from the Surveillance, Epidemiology, and End Results database. The sample was stratified by race/ethnicity, and associations between tumor characteristics, treatment, and survival were assessed.
Of 33,672 patients, the mean age was 65 years, and 77% were male. By race, 17,150 (51%) were white, 4755 (14%) black, 6850 (20%) Hispanic, and 4917 (15%) Asian. When assessing the likelihood of treatment versus no treatment for tumors less than 5 cm, no difference was observed between whites and blacks in any year, but Hispanics were less likely than whites to receive treatment in most years. Asians were more likely to receive treatment every year. When assessing the likelihood of transplant versus surgical resection, blacks were less likely than whites to undergo transplant in all years except 2016. Hispanics were equally likely, while Asians were less likely to undergo transplant in all years. For years 2012 to 2016 collectively, Asians had better 5-year survival rates than other races after undergoing ablation and resection. No difference in the risk of death was observed among blacks, whites, or Hispanics after undergoing ablation, resection, or transplant.
Racial disparities for blacks and Hispanics have improved. Although Asians were less likely to undergo transplant, they had better survival after undergoing resection or ablation.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Kulik L and El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156:477-491.
Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191-199.
National Comprehensive Cancer Network. Hepatobiliary Cancers (Version 2.2020). Accessed May 30, 2020. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf
Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta analysis: Underutilization and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther. 2013;38:703-712.
Jones PD, Scheinberg AR, Muenyi V, Gonzalez-Diaz J, Martin PM, Kobetz E. Socioeconomic and survival differences among minorities with hepatocellular carcinoma in Florida. J Hepatocell Carcinoma. 2019;6:167-181.
Ha J, Yan M, Aguilar M, Tana M, Liu B, Frenette CT, Bhuket T, Wong RJ. Race/Ethnicity-specific disparities in hepatocellular carcinoma stage at diagnosis and its impact on receipt of curative therapies. J Clin Gastroenterol. 2016;50:423-430.
Hoehn RS, Hanseman DJ, Wima K, Ertel AE, Paquette IM, Abbott DE, Shah SA. Does race affect management and survival in hepatocellular carcinoma in the United States? Surgery. 2015;158:1244-1251.
Rich NE, Hester C, Odewole M, Murphy CC, Parikh ND, Marrero JA, Yopp AC, Singal AG. Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2019;17:551-559.
Xu L, Kim Y, Spolverato G, Gani F, Pawlik TM. Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States. Hepatobiliary Surg Nutr. 2016;5:43-52.
Hoehn RS, Hanseman DJ, Jernigan PL, Wima K, Ertel AE, Abbott DE, Shah SA. Disparities in care for patients with curable hepatocellular carcinoma. HPB (Oxford). 2015;17:747-752.
Peters NA, Javed AA, He J, Wolfgang CL, Weiss MJ. Association of socioeconomics, surgical therapy, and survival of early stage hepatocellular carcinoma. J Surg Res. 2017;210:253-260.
Robbins AS, Cox DD, Johnson LB, Ward EM. Persistent disparities in liver transplantation for patients with hepatocellular carcinoma in the United States, 1998 through 2007. Cancer. 2011;117:4531-4539.
Stewart SL, Kwong SL, Bowlus CL, Nguyen TT, Maxwell AE, Bastani R, Chak EW, Chen MS Jr. Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012. World J Gastroenterol. 2016;22:8584-8595.
Sonnenday CJ, Dimick JB, Schulick RD, Choti MA. Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. J Gastrointest Surg. 2007;11:1636-1646.
Gaffney A and McCormick D. The Affordable Care Act: Implications for health-care equity. Lancet. 2017;389(10077):1442-1452.
Agarwal A, Katz AJ, Chen RC. The impact of the affordable care act on disparities in private and Medicaid insurance coverage among patients under 65 with newly diagnosed cancer. Int J Radiat Oncol Biol Phys. 2019;105(1):25-30.
National Cancer Institute, DCCPS, Surveillance Research Program. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 9 Registries, Nov 2018 Sub (1975-2016). Released April 2019, based on the November 2018 submission.
Edge SB, American Joint Committee on Cancer, eds. AJCC Cancer Staging Manual 7th Edition. Springer; 2010.
Jones PD, Diaz C, Wang D, Gonzalez-Diaz J, Martin P, Kobetz E. The impact of race on survival after hepatocellular carcinoma in a diverse American population. Dig Dis Sci. 2018;63:515-528.
Mathur AK, Osborne NH, Lynch RJ, Ghaferi AA, Dimick JB, Sonnenday CJ. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma. Arch Surg. 2010;145:1158-1163.
Artinyan A, Mailey B, Sanchez-Luege N, Khalili J, Sun C, Bhatia S, Wagman LD, Nissen N, Colquhoun SD, Kim J. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer. 2010;116:1367-1377.
Liu JH, Chen PW, Asch SM, Busuttil RW, Ko CY. Surgery for hepatocellular carcinoma: Does it improve survival? Ann Surg Oncol. 2004;11:298-303.
Yu JC, Neugut AI, Wang S, Jacobson JS, Ferrante L, Khungar V, Lim E, Hershman DL, Brown RS Jr, Siegel AB.. Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer. 2010;116:1801-1809.
Siegel AB, McBride RB, El-Serag HB, Hershman DL, Brown RS Jr, Renz JF, Emond J, Neugut AI. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol. 2008;103:120-127.
Devaki P, Wong RJ, Marupakula V, Nangia S, Nguyen L, Ditah IC, Ehrinpreis MN, Nguyen MH. Approximately one-half of patients with early-stage hepatocellular carcinoma meeting Milan criteria did not receive local tumor destructive or curative surgery in the post-MELD exception era. Cancer. 2014;120:1725-1732.
Wong RJ and Corley DA. Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States. Dig Dis Sci. 2009;54:2031-2039
Kemmer NM and Neff GW. Liver transplantation trends and survival in the Asian population. Transplantation. 2009;88:392-394.
Christians KK, Pitt HA, Rilling WS, Franco J, Quiroz FA, Adams MB, Wallace JR, Quebbeman EJ. Hepatocellular Carcinoma: Multimodality Management. Surgery. 2001;130(4):554-560.
Lo CM. Deceased donation in Asia: Challenges and opportunities. Liver Transpl. 2012;18 Suppl 2:S5-7.
Chen C-L, Kabiling CS and Concejero AM. Why does living donor liver transplantation flourish in Asia? Nat Rev Gastroenterol Hepatol. 2013;10:746-751.
Alawadi ZM, Phatak UR, Kao LS, Ko TC, Wray CJ. Race not rural residency is predictive of surgical treatment for hepatocellular carcinoma: Analysis of the Texas Cancer Registry. J Surg Oncol. 2016;113:84-88.
Wang J, Ha J, Lopez A, Bhuket T, Liu B, Wong RJ. Medicaid and uninsured hepatocellular carcinoma patients have more advanced tumor stage and are less likely to receive treatment. J Clin Gastroenterol. 2018;52:437-443.
Nathan H, Hyder O, Mayo SC, Hirose K, Wolfgang CL, Choti MA, Pawlik TM. Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg. 2013;258:1022–1027.
Fagenson AM, Gleeson EM, Pitt HA, Lau KN. Albumin-Bilirubin Score vs Model for End-Stage Liver Disease in Predicting Post-Hepatectomy Outcomes. J Am Coll Surg. 2020;230(4):637–645.
Conflict of Interest
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The abstract of this manuscript was presented virtually at the American College of Surgeons Annual Clinical Congress in October 2020.
About this article
Cite this article
Moten, A.S., Fagenson, A.M., Pitt, H.A. et al. Recent Improvements in Racial Disparity in the Treatment of Hepatocellular Carcinoma: How Times Have Changed. J Gastrointest Surg (2021). https://doi.org/10.1007/s11605-021-04912-7
- Hepatocellular carcinoma